© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Based on recent data, Kiniksa Pharmaceuticals, Ltd. (KNSA) shows an Average True Range (ATR) of 1.43 and an Enterprise Value of 1.05B. Its average trading volume over the past 3 months is 419.88K, indicating liquidity. These fundamental metrics provide insight into KNSA's underlying financial health and market activity.
Kiniksa Pharmaceuticals, Ltd. (KNSA) technical indicators as of December 22, 2025: the SMA 20 is 3.95%, SMA 50 at 7.65%, and SMA 200 at 36.76%. The RSI 14 value is 65.72, suggesting its current momentum. These technical analysis signals help assess KNSA's price trends and potential future movements.
Kiniksa Pharmaceuticals, Ltd. (KNSA) stock performance overview as of December 22, 2025: The 52-week high is $43.73 (currently 0.49% below), and the 52-week low is $17.82 (currently 142.37% above). Over the past year, KNSA's performance is 113.81%, compared to the S&P 500's 12.87% change.
According to market data, Kiniksa Pharmaceuticals, Ltd. (KNSA) stock's recent performance metrics show that over the last month, KNSA is 4.63%, with a Year-to-Date (YTD) performance of 118.35%. Over the past year, the stock has seen a 113.81% change. These figures summarize KNSA's price movements across various periods, reflecting its historical returns.
According to current financial data, KNSA stock's P/E (TTM) ratio is 88.51, which compares to the S&P 500's P/E of 32.59. The sector median P/E is -1.24. Key valuation ratios for KNSA, including P/S (5.29), P/B (5.94), and P/FCF (31.11), offer insights into how the company is valued relative to its earnings, sales, book value, and free cash flow.